Intermittent Fasting in Dyslipidemia
Role of Intermittent Fasting in Improving High Density Lipoprotein Cholesterol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
INTRODUCTION:
Overall lipid profile is important in cardiovascular diseases but particularly serum HDL levels have long been recognized as an independent inverse prognostic marker of CVD, when the Framigham study, in 1980s showed that HDL below 40-60mg/dl is of prognostic relevance. A rise of 1mg/dl in HDL levels is considered to reduce coronary artery disease (CAD) risk to 2-3%. Even patients with elevated total cholesterol (TC) and LDL, presenting a high HDL are seen to be protected from atherosclerosis. Multiple human population studies have shown the concentration of HDL cholesterol as an independent, inverse predictor of the risk of having a cardiovascular event. Additionally, HDL has several well-documented functions with the potential to protect against cardiovascular diseases. These include an ability to promote the efflux of cholesterol from macrophages in the artery wall, inhibit the oxidative modification of LDL, inhibit vascular inflammation, inhibit thrombosis, promote endothelial repair, promote angiogenesis, anti-oxidant, enhance endothelial function, improve diabetic control, and inhibit hematopoietic stem cell proliferation. HDL also exerts direct cardio protective effect, which are mediated with its interactions with the myocardium.
Various studies have emphasised the high incidence of CVD within the South Asian countries. The increased risk of cardiovascular events in South Asians at a younger age might be due to unknown factors affecting plaque rupture, the interaction between prothrombotic factors and atherosclerosis, or may be due to any undiscovered risk factors. Urbanisation and westernisation is characterised by a distinct increase in the intake of energy dense foods, a decrease in physical activity, and a heightened level of psychosocial stress, all of which promote the development of hyperglycaemia, hypertension, and dyslipidaemia. Most common dyslipidaemia in South Asians is low HDL-C and high triglycerides. High triglyceride and low HDL-C levels are metabolically interlinked. This metabolic phenotype is also associated with increased levels of small LDL particles despite relatively normal levels of LDL-C among South Asians. This clinical syndrome is accompanied by insulin resistance, a condition frequently referred to as atherogenic dyslipidemia, which is a common metabolic derangement among Asian. South Asians not only have lower HDL levels but also have a higher concentration of small, less-protective HDL particles. One proposed mechanism is presence of dysfunctional HDL particles. Another potential explanation for the apparent blunted cardioprotection of HDL in South Asians might be related to HDL particle size. Small particles might be less efficient in reverse cholesterol transport. In general, HDL particle size tends to be lower in patients with CHD and those with low HDL-C levels . Alarmingly, an estimated 60-80% of Pakistani population has been reported to have low HDL. There are a number of non-pharmacological and pharmacological recommendations for management of low HDL. Non-pharmacological (functional food) strategies are reported to increase HDL levels around 10-15% and which include regular exercise , body weight reduction in obese individuals , cessation of cigarette smoking in smokers and dietary modifications like decrease intake of saturated trans-fatty acids with increase intake of omega-3 polyunsaturated fatty acids . There are also a number of pharmacological agents being considered as therapeutic options but the tolerability and safety issues limit their use in addition to limited success in improving HDL. IF may be a dietary method to aid in the improvement of the lipid profile in healthy, obese and dyslipidemia men and women, reducing total cholesterol, LDL, triglycerides and increasing HDL levels. However, the majority of studies that analyze the IF impacts on the lipid profile and body weight loss are observational and lack detailed information about diet. Randomized clinical trials with larger sample size are needed to evaluate the IF effects mainly in population with dyslipidemia.
HYPOTHESIS:
Intermittent fasting is capable of improving dyslipidemia and particularly enhancement of serum, HDL which can increase the cardioprotection in high risk general population.
OBJECTIVES:
To evaluate the effect of intermittent fasting on cholesterol levels specifically on HDL.
DATA STORAGE AND MANAGEMENT:
Every participant will be given a code number, all data will be saved according to the code numbers. Privacy will be maintain of each and every participant. Records will be kept confidential and used only for scientific purposes by authorized personnel. The hard copies will be kept in locked cupboards and soft data will be managed in password protected computers. Data will be stored at institutional level for almost 15 years.
DISSEMINATION OF FINDINGS AND PUBLICATION PLAN:
Investigators expect that Ajwa and intermittent fasting will significantly improve HDL levels in order to enhance the cardiac protection. This research will help in promoting the significance of use of functional food and fasting to improve overall health. Investigators expect at least two publications from this study. The findings of the study will be presented in international conference and will be published in well reputed journal.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 74800
- Recruiting
- Aga Khan University
-
Contact:
- Javeria Farooq, D. Pharm, Masters
- Phone Number: 4493 02134860051
- Email: javeria.farooq@aku.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- General population with serum HDL less than 40 mg/dl for men and women
- Adult ages 18- 80 years will be included in the study.
Exclusion Criteria:
- Individuals Patients already observing fasting regularly
- Pregnant women and individuals with diabetes, metabolic syndrome or any other co-morbidity will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control
|
|
|
Experimental: Interventional
Will observe intermittent fasting
|
12-14 hours fasting
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lipid profile
Time Frame: 6 weeks
|
Change in HDL more than 3mg/dl Change in LDL more than 3mg/dl Cholesterol and TG
|
6 weeks
|
|
weight loss
Time Frame: 6 weeks
|
Change in body weight (kg), as measured by scale weight
|
6 weeks
|
|
Blood pressure
Time Frame: 6 weeks
|
Reduction in systolic and diastolic
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting Glucose
Time Frame: 6 weeks
|
Fasting glucose mg/dl
|
6 weeks
|
|
Fasting Insulin
Time Frame: 6 weeks
|
Fasting insulin (IU/L)
|
6 weeks
|
|
Waist circumference Waist circumference (cm)
Time Frame: 6 weeks
|
WC in cm
|
6 weeks
|
|
Lipid profile HbA1c (%) Lipids
Time Frame: 6 weeks
|
Total cholesterol (mg/dl), LDL cholesterol (mg/dl), HDL cholesterol (mg/dl), and triglycerides (mg/dl)
|
6 weeks
|
|
Waist circumference
Time Frame: 6 weeks
|
Waist circumference (cm)
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Hammouda O, Chtourou H, Aloui A, Chahed H, Kallel C, Miled A, Chamari K, Chaouachi A, Souissi N. Concomitant effects of Ramadan fasting and time-of-day on apolipoprotein AI, B, Lp-a and homocysteine responses during aerobic exercise in Tunisian soccer players. PLoS One. 2013 Nov 11;8(11):e79873. doi: 10.1371/journal.pone.0079873. eCollection 2013.
- Ahmed N, Farooq J, Siddiqi HS, Meo SA, Kulsoom B, Laghari AH, Jamshed H, Pasha F. Impact of Intermittent Fasting on Lipid Profile-A Quasi-Randomized Clinical Trial. Front Nutr. 2021 Feb 1;7:596787. doi: 10.3389/fnut.2020.596787. eCollection 2020.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 123 (Giresun University Scientific Research Project)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Diseases
-
NCT05630729CompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage I
-
NCT03142529UnknownEnd-Stage Kidney Disease | Chronic Kidney Failure
-
NCT03196076CompletedChronic Kidney Diseases | Cystic Kidney Disease
-
NCT04336033RecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic Dialysis
-
NCT05747053TerminatedKidney Diseases | Kidney Failure, Chronic | Kidney Transplant Infection | Kidney Transplant Rejection | Kidney Injury | Kidney Disease, Chronic | Kidney Failure | Kidney Failure, Acute | Kidney Transplant; Complications | Kidney Ischemia
-
NCT02235571CompletedKidney Failure, Chronic | Kidney Transplantation | End-Stage Kidney Disease
-
NCT01890811Withdrawn
-
NCT03068195UnknownKidney Diseases,Cystic
-
NCT03998917WithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
NCT01232257CompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney Failure
Clinical Trials on Fasting (diet restruction for specific period)
-
NCT04292041UnknownMetabolic Syndrome | Prostate Cancer | Intermittent Fasting
-
NCT01220037CompletedSingle Bout of Resistance Type Exercise | Standardized Diet
-
NCT05728385Not yet recruiting
-
NCT07318727Recruiting
-
NCT07057999CompletedMultiple Sclerosis | Body Composition | Fatigue Syndrome, Chronic | Diet Therapy | Brain Fog | Randomised Controlled Trial | Quality of Life (QOL)
-
NCT07047573RecruitingPulmonary Nodule Persistent | Lung Cancer (Diagnosis)
-
NCT03423069CompletedIrritable Bowel Syndrome
-
NCT04871165RecruitingAnalysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed IndividualsHematologic Neoplasms | COVID-19 Vaccines
-
NCT04082559Recruiting